Recent Updates
Recently added Catalysts
LEGN

Legend Biotech to Present at the Jefferies Virtual Healthcare Conference SOMERSET, N.J.--(BUSINESS WIRE)

Key Takeaway: Legend Biotech to Present at the Jefferies Virtual Healthcare Conference SOMERSET, N.J.--(BUSINESS WIRE)--May 25, 2021--Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech"), a global clinical-stage biopharmaceutical company engaged in the discovery and development of nov

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+118%
120-day peak, hindsight
Typical move
18.4%
average across 6 past catalysts
Lead asset
LUCAR-DKS1 NK cells
Phase 1 · Relapsed/Refractory Autoimmune Diseases

Full Press Release Details

Legend Biotech to Present at the Jefferies Virtual Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)--May 25, 2021--Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech"), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and
other indications, today announced it will present at the Jefferies Virtual Healthcare Conference on June 3, 2021 at 9:30 am ET. This webcast will be available to investors and other interested parties by accessing the Legend Biotech website at
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and
Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need.
We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, cilta-cel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being
studied in registrational clinical trials.
Last updated: May 25, 2021